Replies to post #228381 on Biotech Values

[jq1234]

GILD is testing its oral PD-L1 inhibitor GS-4224 for both solid tumors and HBV.

[jondoeuk]

In this preclinical paper NUC therapy, (DNA) vaccination and an anti-PD-L1 (not indefinitely) led to viral clearance in a subset [1]. Also, clinical data on PD-1 receptor occupancy (and more) after a single infusion of Opdivo was provided in this [2]. So I think anti-PD(L)-1 inhibitors could play a role in a potentially 'curative' regimen, but the real question is how many agents will be needed.

1 https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003856
2 https://www.journal-of-hepatology.eu/article/S0168-8278(19)30400-3/fulltext

[DewDiligence]

Ascletis Pharma starts phase-2a of PD-L1 in HBV:

https://www.prnewswire.com/news-releases/first-hbv-patient-dosed-in-phase-iia-clinical-trial-of-asc22-a-subcutaneously-administered-pd-l1-antibody-301112931.html

As T cell exhaustion in chronic HBV infections is an important factor in immune tolerance, blocking the PD-1/PD-L1 pathway could be an effective immunotherapy approach to improve specific T cell function and lead to an effective clinical cure for chronic hepatitis B.

The trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT04465890 .